Based on targeted product profile assessments, physicians project notable uptake following approval, with use concentrated among DM patients in need of durable, steroid-sparing efficacy. Beyond ...

NEW ORLEANS — A monoclonal antibody targeting interferon beta (IFN-beta) provided substantial reductions in the skin lesions associated with dermatomyositis in a double-blind, placebo-controlled phase ...

Matthew Herper covers medical innovation — both its promise and its perils. The biotech firm Roivant and its spinout Priovant said Wednesday that their immune-modifying drug brepocitinib outperformed ...

We recently published All-Time Rush: 8 of 10 Big Names Hit Fresh Record Highs. Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best performers on Wednesday. Roivant Sciences jumped to a new all-time ...

Head and neck cancer (HNC) occurred in a small but distinct subgroup of patients with dermatomyositis (DM), in a retrospective study that also found that most cases presented with myositis and neck ...

Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all nine key secondary endpoints, ...